Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Chronic Plaque Psoriasis Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market for chronic plaque psoriasis has seen robust growth in the past few years. Its size is projected to increase from $20.79 billion in 2024 to $22.32 billion in 2025, signifying a compound annual growth rate (CAGR) of 7.3%. This expansion during the historic era is credited to the escalating incidence of psoriasis and associated co-morbidities, favorable insurance reimbursement strategies, growing alcohol and smoking use, and the emergence of telemedicine.

In the coming years, the market size for chronic plaque psoriasis is projected to experience a substantial increase, with a valuation of $29.33 billion in 2029, reflecting a compound annual growth rate (CAGR) of 7.1%. The growth within this forecast period is likely due to the global rising or falling prevalence of cpp, an increase in autoimmune diseases, expansion in healthcare budgets, aging demographic, and a growing demand for effective treatments. The period is also expected to see significant trends such as advancements in biologic treatments, oral small molecule inhibitors, digital health integration, personalized medicine, and the advent of biosimilars.

What Drivers Are Shaping the Growth of the Chronic Plaque Psoriasis Market?

Growth in the chronic plaque psoriasis market is projected to be fueled by the uptick in immune system dysfunction cases. When the immune system is ineffective, it is referred to as immune system dysfunction, leading to heightened vulnerability to infections, autoimmune diseases, and cancer. Factors such as genetic predisposition, environmental influences, malnutrition, chronic stress, and a surge in infections like HIV and autoimmune diseases are driving the increase in immune system dysfunction cases. Chronic plaque psoriasis treatment is vital to control immune system dysfunction because the immune system unintentionally triggers excessive skin cell production, resulting in inflammation and plaque formation. For instance, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, stated that psoriasis impacts over 8 million Americans. Worldwide, 125 million people are affected by this condition, representing 2 to 3% of the global population. Consequently, the rise in incidents of immune system dysfunction is propelling the chronic plaque psoriasis market’s growth.

Get Your Free Sample of the Global Chronic Plaque Psoriasis Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Who Are the Influential Players Reshaping the Chronic Plaque Psoriasis Market Landscape?

Major companies operating in the chronic plaque psoriasis market are:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

• Bristol-Myers Squibb Company_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Chronic Plaque Psoriasis Market?

Leading enterprises in the chronic plaque psoriasis market are prioritizing the development of novel therapies, such as IL-17A and IL-17F inhibitors, to achieve progress in treating chronic plaque psoriasis. These inhibitors are specialized biologic treatments that suppress interleukin-17A and interleukin-17F, substances that trigger inflammatory responses in the immune system, aiming to decrease inflammation in autoimmune conditions such as chronic plaque psoriasis. As an example, in October 2023, UCB S.A., a biopharmaceutical firm from Belgium, publicized that the U.S. Food and Drug Administration (FDA) approved its medication BIMZELX (bimekizumab-bkzx) for adult patients suffering from moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. Bimekizumab is the pioneering medication given approval for psoriasis with the specific purpose to target and hinder interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both crucial elements in inflammatory occurrences. Its endorsement comes from gathered data from three Phase 3 multicenter studies—BE READY, BE VIVID, and BE SURE—these studies evaluated its safety and effectiveness in 1,480 patients with moderate to severe plaque psoriasis.

Get Instant Access to the Global Chronic Plaque Psoriasis Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Chronic Plaque Psoriasis Market?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Which Geographic Locations Are Critical to the Growth of the Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Chronic Plaque Psoriasis Market?

Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

Browse Through More Similar Reports By The Business Research Company:

Psoriasis Global Market Report 2025

https://thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Global G-CSF (Granulocyte Colony Stimulating Factors) Opportunities And Strategies Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: